High-Dose Intravenous Iron Replacement Therapy for Iron Deficiency Anemia Does Not Hinder Drug-Induced Amelioration of Disease Activity in IBD Patients
February 2018
in “
The American Journal of Gastroenterology
”
TLDR High-dose iron therapy improves anemia without affecting IBD treatment.
The study assessed the impact of high-dosed intravenous ferric carboxymaltose (FCM) on inflammatory activity in 224 IBD patients across 101 centers in Germany. Over approximately 12 weeks, patients received a mean total iron dose of 1,139mg. The study found that FCM therapy did not hinder the drug-induced reduction of inflammatory activity, as indicated by significant decreases in CRP levels and clinical disease activity indices (CDAI/CAI). Patients experienced improvements in hemoglobin, s-ferritin, and TSAT levels, along with reduced symptoms. The results suggested that high-dosed FCM is effective and does not interfere with the amelioration of disease activity in IBD patients.